¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"half survival time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Æø·Î½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
  • forced expiratory time
    ³ë·Â³¯¼û½Ã°£, °­Á¦È£±â½Ã°£
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • intraretinal transit time
    ¸Á¸·³»ÀÌÇà½Ã°£
  • inversion time
    ¿ªÀü½Ã°£
  • ischemic time
    ÇãÇ÷½Ã°£
  • inertia time
    ºÒȰµ¿½Ã°£, Ÿ¼º½Ã°£
  • influx time
    À¯ÀԽð£
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£, Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£
  • interaural time difference
    ¾ç±Í°£µµ´Þ½Ã°£Â÷
  • intraatrial conduction time
    ½É¹æ³»Àüµµ½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
  • time cluster
    ½Ã°£Áý¶ô¼º
  • time cue
    ½Ã°£½ÅÈ£ÀÎÀÚ
  • time compensation curve
    ½Ã°£º¸»ó°î¼±
  • time-activity curve
    ½Ã°£¹æ»ç´É°î¼±
  • time-kill curve
    ½Ã°£»ç¸ê°î¼±
  • time-motion curve
    ½Ã°£¿îµ¿°î¼±
  • time-place cluster
    ½Ã°£Áö¿ªÁý¶ô¼º
  • dead time
    ºÒÀÀ½Ã°£
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • interaural time difference
    ¾ç±Í°£µµ´Þ½Ã°£Â÷
  • real time display
    ½Ç½Ã°£Ç¥½Ã, ½ÇÁ¦½Ã°£Ç¥½Ã
  • expiratory pause time
    ³¯¼ûÈĽ¬´Â½Ã°£, È£±âÈÄÈÞÁö½Ã°£
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • activated partial thromboplastin time =aPTT
    Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • appearance time
    ÃâÇö½Ã°£(õóúÞãÁÊà) ¼øÈ¯(âàü») .
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • arm to tongue time test
    ÆÈÇô¼øÈ¯½Ã°£½ÃÇè
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£, ¿Ï-¸Á¸·¼øÈ¯½Ã°£
  • gastric emptying time
    À§(êÖ)(³»¿ë(Ò®é»))¹èÃâ½Ã°£(ÛÉõóãÁÊà).
  • gastric emptying time
    À§(³»¿ë)¹èÃâ½Ã°£.
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • hardening time
    °æÈ­½Ã°£(¡­ãÁÊà).
  • inertia time
    Ÿ¼º½Ã°£(öçàõãÁÊà)
  • influx time
    À¯ÀԽð£(êüìýãÁÊà).
  • inspiratory pause time
    Èí±âÈÄÈÞÁö½Ã°£.
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • half normal solution
    0.5 ±ÔÁ¤¾×(¡­Ð®ïÒäû).
  • half round tube
    ¹Ý¿ø°ü(Úâê­Î·) ±³Á¤¿ë(ÎìïáéÄ) .
  • half round wire
    ¹Ý¿ø¼±(Úâê­àÊ) ±³Á¤¿ë .
  • half shell crown
    ¹Ý±Ý°ü.
  • half spherical cavity
    ¹Ý±¸Çü¿Íµ¿(ÚâϹû¡èÀ÷Ó).
  • half tone =semitone
    ¹ÝÀ½
  • half value layer =HVL
    [¾È°ú]¹Ý°¡Ãþ(Úâʤöµ).
  • half vision
    Çü»ó½Ã(û¡ßÒãÊ).
  • half waking somnombulism
    ¹Ý°¢¼º ¸ùÀ¯(º´)(ÚâÊÆá¥ÙÓë´Ü»).
  • half-life
    ¹Ý°¨±â
  • half-value layer
    ¹Ý°¡Ãþ
  • one and one-half syndrome
    1 1/2 ÁõÈıº
  • period of half decay
    ¹Ý¼è±â(ÚâáñÑ¢).
  • physical half life
    ¹°¸®Àû ¹Ý°¨±â(ÚªìµîÜ ÚâÊõÑ¢).
  • physical half-life
    ¹°¸®Àû¹Ý°¨±â
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • T2 (spin spin) relaxation time
    T2(½ºÇɽºÇÉ)À̿Ͻð£
  • T2 relaxation time
    T2À̿Ͻð£
  • temporal window(scan time)
    ÀϽÃÀû â
  • time compensation curve
    ½Ã°£º¸»ó°î¼±
  • time gain compensation [=T.G.C.]
    ½Ã°£°ÔÀκ¸»ó
  • time gain compenstaion curve
    ½Ã°£°ÔÀκ¸»ó°î¼±
  • time gain control
    ½Ã°£°ÔÀÎÁ¶Àý
  • time interval
    ½Ã°£°£°Ý
  • time motion curve
    ½Ã°£¿îµ¿°î¼±
  • time of flight [=TOF]
    È帧½Ã°£, À¯Ã¼¼Óµµ°­Á¶
  • time of flight MR angiography
    À¯Ã¼¼Óµµ°­Á¶ ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • time of flight phenomenon
    À¯Ã¼¼Óµµ°­Á¶Çö»ó
  • time sharing
    ½Ã°£°øÀ¯, ½ÃºÐÇÒ
  • time velocity integral
    ½Ã°£¼ÓµµÁ¤¼ö
  • TM scan(Time motion)
    ½Ã°£¿îµ¿¹æ½Ä
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TTI tension-time index; time-tension index; timepto-intubation; torque-time interval; transtracheal insu...
5 YSR 5 Year Survival Rate
YSR Year Survival Rate
CDS cardiovascular surgery; catechol-3, 5-disulfonate; caudal dysplasia syndrome; Chemical Data System; ...
CONSENSUS Cooperative North Scandinavian Enalapril Survival Study
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
T 1/2 The elimination half life
T 1/2 The half lives
T 1/2 The mean half-life
VHF Visual Half-Field
FWHM full width half maximum
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • relaxation time
    ÀÌ¿Ï ½Ã°£
  • retention time
    ÀÜ·ù ½Ã°£
  • setting time
    °æÈ­ ½Ã°£, ÀÀ°í ½Ã°£, ±»´Â ½Ã°£
    1. ºñÄÏ Ä§À» »ç¿ëÇÏ¿© ¿¬È­ °³½Ã¿¡¼­ ħÀÔ±íÀ̰¡ 1§® ÀÌÇϰ¡ µÉ ¶§±îÁöÀÇ ½Ã°£À» °æÈ­ ½Ã°£À̶ó ÇÑ´Ù. ¾ö¹ÐÈ÷ Ãʱ⠰æÈ­ ½Ã°£ÀÌ´Ù. 2. È¥ÇÕ ½ÃÀÛºÎÅÍ Àç·á°¡ ÃæºÐÇÏ¿© ÀÓ»óÀûÀ¸·Î À¯ÀǼºÀÌ ÀÖ´Â ¿µ±¸ º¯Çü ¾øÀÌ ÀλóÀ» ±¸°­ ³»¿¡¼­ Á¦°ÅÇÒ ¼ö Àִµ¥ ¼Ò¿äµÇ´Â ÃÖ¼ÒÇÑÀÇ ½Ã°£.
  • T2 relaxation time
    T2 ÀÌ¿Ï ½Ã°£
  • T2 spin spin relaxation time
    T2 ½ºÇÉ ½ºÇÉ ÀÌ¿Ï ½Ã°£
  • thermal camera time response
    ¿­ Ä«¸Þ¶ó ½Ã°£ ¹ÝÀÀ
  • time
    ½Ã°£, ¶§
    ¾î¶² ½Ã°¢°ú ½Ã°¢ÀÇ »çÀÌ.
  • time cycled ventilator
    ½Ã°£ ÁÖ±â È£Èí±â
  • time difference
    ½ÃÂ÷
  • time gain compensation
    ½Ã°£ °ÔÀÎ º¸»ó
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
  • time lag
    Áöü ½Ã°£
  • time of death
    »ç¸Á ½Ã°¢
  • time of flight
    È帧 ½Ã°£, À¯Ã¼ ¼Óµµ °­Á¶
  • time of flight phenomenon
    À¯Ã¼ ¼Óµµ °­Á¶ Çö»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
activated partial thromboplastin time The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system.
(05 Mar 2000)
A-H conduction time Forward conduction of the cardiac impulse from atria to ventricles via the A-V node or any bypass tract, represented in the electrocardiogram by the P-R interval. P-H conduction time is from the onset of the P wave to the first high frequency component of the His bundle electrogram (normally 119 ± 38 msec); A-H conduction time is from the onset of the first high frequency component of the atrial electrogram to the first high frequency component of the His bundle electrogram (normally 92 ± 38 msec); P-A conduction time is from the onset of the P wave to the onset of the atrial electrogram (normally 27 ± 18 msec).
(05 Mar 2000)
association time Time elasping between a stimulus and the verbalised response to it.
(05 Mar 2000)
biologic time The concept that our appreciation of time varies with age and is governed by the neural organization of the individual; it obeys a logarithmic rather than an arithmetic law.
(05 Mar 2000)
bleeding time <haematology> A test which measures the time it takes for small blood vessels to close off and bleeding to stop. Abnormal results can be seen in those with congenital or acquired platelet function disorders or thrombocytopenia.
(27 Sep 1997)
blood circulation time Determination of the shortest time interval between the injection of a substance in the vein and its arrival at some distant site in sufficient concentration to produce a recognizable end result. It represents approximately the inverse of the average velocity of blood flow between two points.
(12 Dec 1998)
P-A conduction time See: atrioventricular conduction.
(05 Mar 2000)
generation time <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle.
(18 Nov 1997)
reaction time The time from the onset of a stimulus until the organism responds.
(12 Dec 1998)
real-time ultrasonography Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion.
(05 Mar 2000)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
relaxation time Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value.
(18 Nov 1997)
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
repetition time In magnetic resonance imaging, the time between repetitions of the pulse sequence.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • half moon
    ¹Ý´Þ(ÇüÀÇ °Í)
  • half mourning
    ¹Ý»óº¹;¹Ý»óº¹À» ÀÔ´Â ±â°£;¹Ý»ó±â
  • half nelson
    (·¹½º¸µ) ¸ñ´ú¹Ì Á˱â
  • half nelson
    (·¹½½¸µ)ÇÏÇÁ ³Ú½¼;¸ñ´©¸£±â
  • half note
    2ºÐ À½Ç¥
  • half pay
    ºÀ±ÞÀÇ ¹Ý;¹ÝºÀ;¹Ý±Þ
  • half pint
    ¹Ý ÆÄÀÎÆ®;Á»ÆØÀÌ;º¸Àß°Í ¾ø´Â »ç¶÷
  • half plane
    ¹ÝÆò¸é
  • half sister
    ¹è(¾¾)´Ù¸¥ ÀÚ¸Å
  • half sister
    ¹è(¾¾)´Ù¸¥ ÀÚ¸Å;¾Æ¹öÁö(¾î¸Ó´Ï)¸¸ °°Àº ÀÚ¸Å
  • half size
    ÇÏÇÁ »çÀÌÁî(Ű¿¡ ºñÇØ ¸öÅëÀÌ Å« üÇü¿¡ ¾Ë¸ÂÀº ¿©¼ºº¹ÀÇ »çÀÌÁî);2ºÐÀÇ 1 Ãàô
  • half sole
    (±¸µÎ¿¡)¾Õâ
  • half sole
    (±¸µÎÀÇ)¾Õâ
  • half sovereign
    10½Ç¸µ ±ÝÈ­(1916³â¿¡ ÆóÁö)
  • half step
    ¹ÝÀ½(semitone);¹Ýº¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á